Shares of Ovid Therapeutics (NASDAQ:OVID - Get Free Report) crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $2.50 and traded as low as $2.37. Ovid Therapeutics shares last traded at $2.40, with a volume of 2,796,391 shares traded.
Wall Street Analysts Forecast Growth
OVID has been the topic of a number of research analyst reports. B. Riley Financial restated a "buy" rating on shares of Ovid Therapeutics in a report on Tuesday, July 21st. Cantor Fitzgerald assumed coverage on shares of Ovid Therapeutics in a research report on Friday, October 9th. They issued an "overweight" rating on the stock. Oppenheimer upped their target price on shares of Ovid Therapeutics from $7.00 to $9.00 and gave the stock an "outperform" rating in a research note on Monday, August 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Ovid Therapeutics in a report on Thursday, October 15th. Finally, HC Wainwright lifted their price target on Ovid Therapeutics from $4.00 to $5.00 and gave the company a "buy" rating in a research note on Friday, September 11th. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Ovid Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $6.12.
Get Our Latest Analysis on Ovid Therapeutics
Ovid Therapeutics Price Performance
The company's fifty day moving average is $2.50 and its 200 day moving average is $2.40. The firm has a market cap of $452.95 million, a price-to-earnings ratio of -10.00 and a beta of 0.24. The company has a quick ratio of 12.39, a current ratio of 11.97 and a debt-to-equity ratio of 0.05.
Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). On average, equities research analysts predict that Ovid Therapeutics will post -0.39 EPS for the current year.
Hedge Funds Weigh In On Ovid Therapeutics
Several hedge funds have recently modified their holdings of the stock. Legal & General Group Plc acquired a new stake in shares of Ovid Therapeutics in the second quarter valued at about $40,000. E Fund Management Co. Ltd. acquired a new position in shares of Ovid Therapeutics during the 2nd quarter worth approximately $52,000. Focus Partners Advisor Solutions LLC acquired a new position in shares of Ovid Therapeutics during the 2nd quarter worth approximately $54,000. StoneX Group Inc. acquired a new position in shares of Ovid Therapeutics during the 3rd quarter worth approximately $51,000. Finally, Stonepine Capital Management LLC bought a new stake in shares of Ovid Therapeutics during the 2nd quarter worth approximately $57,297. Institutional investors own 72.24% of the company's stock.
About Ovid Therapeutics
(
Get Free Report)
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for epilepsies and other neurological disorders. Its work targets conditions with significant unmet treatment needs, including rare and difficult-to-treat seizure disorders. The company's lead development program, OV329, is an investigational GABA aminotransferase inhibitor being studied as a potential treatment for seizures, including infantile spasms and focal-onset seizures. Ovid's pipeline and research programs may change as clinical development progresses.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ovid Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ovid Therapeutics wasn't on the list.
While Ovid Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.